Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia SAD study of the oral tablet, ASC30, in obese ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of ...

Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, the weight-loss drug Ozempic is in huge demand ...

VK-2735 may be the first oral GLP-1R to gain approval in obesity. Credit: zimmytws via Shutterstock. Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success in ...